Cambridge Cognition and Actigraph partner on central nervous system trials

Cambridge Cognition, which develops digital solutions to assess brain health, is partnering with ActiGraph, a provider of wearable technologies for clinical trials. The partnership will deliver a suite of assessments to provide a fully rounded view of mental and physical capabilities. 

ActiGraph’s Accelerant partnership program is designed to advance the use of digital health technologies (DHTs) in clinical development by simplifying CROs’ and technology vendors’ access to raw data streams. As part of this strategic partnership, Cambridge Cognition and ActiGraph will combine their collective expertise in digital data collection to enhance assessment capabilities in CNS trials in areas where there is a large unmet need, such as schizophrenia and dementia.

Cambridge Cognition offers touchscreen and voice-based digital assessments of cognition and other brain health indicators that have been based on over 30 years of work. The company’s suite of e-clinical technology solutions can be used at home or in-clinic.

Francesca Cormack, chief scientist, Cambridge Cognition, said: “CNS disorders are characterised by a host of heterogeneous symptoms which impact daily life, but that are often inadequately addressed by existing treatments. Our partnership with ActiGraph represents an exciting combination of expertise in objective digital measures of actigraphy, speech and cognition that will help accelerate the development of treatments for patients and improve efficiency in clinical trials.”

Christine Guo, chief scientific officer, ActiGraph, added: "Digital health technologies give us the ability to collect data objectively during a patient’s everyday life. This is especially important in CNS disorders where conventional assessments are prone to subjective biases. We are excited about this partnership with Cambridge Cognition to provide advanced clinical insights to study teams conducting CNS trials.”